Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Fergus J. Couch(Mayo Clinic), Theo A. van Os(Amsterdam UMC Location University of Amsterdam), Tomas Kirchhoff(Memorial Sloan Kettering Cancer Center), Jan Lubiński(Tumour Institute of Tuscany), Tomasz Byrski(International Hereditary Cancer Center), Tomasz Huzarski(International Hereditary Cancer Center), Hans Ehrencrona(Lund University), Antonis C. Antoniou(Weatherford College), María‐Isabel Tejada(BioCruces Health research Institute), Ana Osório(Spanish National Cancer Research Centre), Daniel Barrowdale(University of Cambridge), Bohdan Górski(International Hereditary Cancer Center), Susan J. Ramus(Cancer Institute of New South Wales), Irene L. Andrulis(University of Toronto), Javier Benı́tez(Spanish National Cancer Research Centre), Anna Marie Mulligan, Maria Soller(Karolinska University Hospital), Anna Jakubowska(Pomeranian Medical University), Susan M. Domchek(University City Science Center), Ute Hamann(German Cancer Research Center), Katherine L. Nathanson(Translational Therapeutics (United States)), Anne‐Marie Gerdes(Copenhagen University Hospital), Mia M. Gaudet(Cancer Prevention Institute of California), Gisela Barbany(Karolinska Institutet), Xianshu Wang(Kunming University of Science and Technology), Uffe Birk Jensen(Aarhus University Hospital), M. Durán(Universidad de Valladolid), Per Karlsson(University of Gothenburg), Elżbieta Złowocka(University of Southern California), Jacek Gronwald(International Hereditary Cancer Center), Andrew Lee(University of Cambridge), Jonathan Beesley(The University of Melbourne), Anne‐Bine Skytte(Aarhus University Hospital), Cezary Cybulski(International Hereditary Cancer Center), Frans B.L. Hogervorst(The Netherlands Cancer Institute), Katarzyna Jaworska(International Hereditary Cancer Center), Katarzyna Durda(Pomeranian Medical University), Hilmi Özçelik(Mount Sinai Hospital), Lesley McGuffog(University of Cambridge), Torben A. Kruse(Odense University Hospital), Sue Healey(QIMR Berghofer Medical Research Institute), Timothy R. Rebbeck(University of Pennsylvania), Mads Thomassen(Odense University Hospital), Niklas Loman(Lund University), Penny Soucy(University of Cambridge), Olga M. Sinilnikova(Hospices Civils de Lyon), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Anna von Wachenfeldt(Karolinska Institutet), Karoline Kuchenbaecker(University of Cambridge)
Cited by 57
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k